Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate Patent Expiration
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate is Used for treating HIV infection with a composition containing a pharmacokinetic enhancer that inhibits cytochrome P450 monoxygenase. It was first introduced by Gilead Sciences Inc
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate Patents
Given below is the list of patents protecting Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Genvoya |
US10039718 (Pediatric) | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Apr 06, 2033 | Gilead Sciences Inc |
| Genvoya |
US8754065 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Genvoya |
US9296769 (Pediatric) | Tenofovir alafenamide hemifumarate | Feb 15, 2033 | Gilead Sciences Inc |
| Genvoya | US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | Oct 06, 2032 | Gilead Sciences Inc |
| Genvoya | US8754065 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Genvoya | US9296769 | Tenofovir alafenamide hemifumarate | Aug 15, 2032 | Gilead Sciences Inc |
| Genvoya |
US8633219 (Pediatric) | Combination therapy | Oct 30, 2030 | Gilead Sciences Inc |
| Genvoya | US8633219 | Combination therapy | Apr 30, 2030 | Gilead Sciences Inc |
| Genvoya |
US8148374 (Pediatric) | Modulators of pharmacokinetic properties of therapeutics | Mar 03, 2030 | Gilead Sciences Inc |
| Genvoya |
US9891239 (Pediatric) | Modulators of pharmacokinetic properties of therapeutics | Mar 03, 2030 | Gilead Sciences Inc |
| Genvoya | US8148374 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Gilead Sciences Inc |
| Genvoya | US9891239 | Modulators of pharmacokinetic properties of therapeutics | Sep 03, 2029 | Gilead Sciences Inc |
| Genvoya |
US7635704 (Pediatric) | Stable crystal of 4-oxoquinoline compound | Apr 26, 2027 | Gilead Sciences Inc |
| Genvoya |
US8981103 (Pediatric) | Stable crystal of 4-oxoquinoline compound | Apr 26, 2027 | Gilead Sciences Inc |
| Genvoya |
US7176220 (Pediatric) | 4-oxoquinoline compound and use thereof as pharmaceutical agent | Feb 27, 2027 | Gilead Sciences Inc |
| Genvoya | US7635704 | Stable crystal of 4-oxoquinoline compound | Oct 26, 2026 | Gilead Sciences Inc |
| Genvoya | US8981103 | Stable crystal of 4-oxoquinoline compound | Oct 26, 2026 | Gilead Sciences Inc |
| Genvoya | US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | Aug 27, 2026 | Gilead Sciences Inc |
| Genvoya |
US7390791 (Pediatric) | Prodrugs of phosphonate nucleotide analogues | Oct 17, 2025 | Gilead Sciences Inc |
| Genvoya | US7390791 | Prodrugs of phosphonate nucleotide analogues | Apr 17, 2025 | Gilead Sciences Inc |
| Genvoya | US7800788 | Upright image processing apparatus with pivotable image reading portion |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
| Genvoya | US7803788 | Prodrugs of phosphonate nucoleotide analogues |
Feb 02, 2022
(Expired) | Gilead Sciences Inc |
| Genvoya |
US6703396 (Pediatric) | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep 09, 2021
(Expired) | Gilead Sciences Inc |
| Genvoya |
US6642245 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May 04, 2021
(Expired) | Gilead Sciences Inc |
| Genvoya | US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar 09, 2021
(Expired) | Gilead Sciences Inc |
| Genvoya | US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov 04, 2020
(Expired) | Gilead Sciences Inc |
| Genvoya |
US5914331 (Pediatric) | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan 02, 2018
(Expired) | Gilead Sciences Inc |
| Genvoya | US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul 02, 2017
(Expired) | Gilead Sciences Inc |
| Genvoya |
US5814639 (Pediatric) | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar 29, 2016
(Expired) | Gilead Sciences Inc |
| Genvoya | US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep 29, 2015
(Expired) | Gilead Sciences Inc |
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List